- Home
- ASND vs QGEN Comparison
ASND vs QGEN Comparison
Compare ASND & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- QGEN
- Stock Information
- Founded
- ASND 2006
- QGEN 1986
- Country
- ASND Denmark
- QGEN Netherlands
- Employees
- ASND N/A
- QGEN N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASND Health Care
- QGEN Health Care
- Exchange
- ASND Nasdaq
- QGEN Nasdaq
- Market Cap
- ASND 8.4B
- QGEN 9.9B
- IPO Year
- ASND 2015
- QGEN 1996
- Fundamental
- Price
- ASND $128.13
- QGEN $46.01
- Analyst Decision
- ASND Strong Buy
- QGEN Buy
- Analyst Count
- ASND 14
- QGEN 8
- Target Price
- ASND $192.07
- QGEN $51.86
- AVG Volume (30 Days)
- ASND 374.2K
- QGEN 818.9K
- Earning Date
- ASND 02-05-2025
- QGEN 02-05-2025
- Dividend Yield
- ASND N/A
- QGEN 2.87%
- EPS Growth
- ASND N/A
- QGEN N/A
- EPS
- ASND N/A
- QGEN 0.41
- Revenue
- ASND $365,187,374.00
- QGEN $1,966,174,000.00
- Revenue This Year
- ASND $9.76
- QGEN $2.78
- Revenue Next Year
- ASND $81.02
- QGEN $5.45
- P/E Ratio
- ASND N/A
- QGEN $110.95
- Revenue Growth
- ASND 115.54
- QGEN 0.62
- 52 Week Low
- ASND $111.09
- QGEN $39.03
- 52 Week High
- ASND $161.00
- QGEN $47.44
- Technical
- Relative Strength Index (RSI)
- ASND 41.36
- QGEN 60.66
- Support Level
- ASND $126.38
- QGEN $45.10
- Resistance Level
- ASND $137.54
- QGEN $46.26
- Average True Range (ATR)
- ASND 5.53
- QGEN 0.75
- MACD
- ASND -1.14
- QGEN 0.06
- Stochastic Oscillator
- ASND 11.21
- QGEN 83.01
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).